By utilizing the company’s proprietary homogenous mobility shift assay (HMSA), the test measures infliximab drug and its antibody levels in inflammatory bowel disease (IBD) patients.

The test also helps physicians to identify potential causes for loss of treatment response and guides patient management decisions.

The company said the loss of treatment response may be the result of insufficient infliximab levels and also due to the development of antibodies to infliximab (ATI).

Prometheus president and chief executive officer Joseph Limber said the launch of Prometheus Anser IFX continues the company’s commitment to advance treatments in personalized medicine for gastroenterologists, patients and healthcare providers.

"PROMETHEUS Anser IFX provides significant value to the IBD patient using infliximab and his or her treating physician – potentially saving time and effort in guiding treatment decisions when response to infliximab is lost," Limber added.